BTK抑制剂治疗套细胞淋巴瘤的临床研究进展

doi:10.3969/j.issn.1006-5725.2024.17.002

Abstract

Abstract:

Mantle cell lymphoma （MCL） is a rare B-cell non-Hodgkin's lymphoma characterized by clinical and pathological features encompassing both indolent and aggressive subtypes. Significant progress has been made in the past decade regarding the development of novel therapeutic options for MCL. Particularly， Bruton's tyrosine kinase inhibitor （BTKi） has exhibited remarkable efficacy in treating patients with MCL by specifically targeting the BTK protein， thereby inhibiting B-cell proliferation and inducing potent anti-tumor effects. Currently， global approval has been granted to five BTK inhibitors for MCL treatment， including the first-generation Ibrutinib， second-generation Acalabrutinib， Zanubrutinib， Orelabrutinib， as well as the non-covalent BTKi Pirtobrutinib. This review provides a comprehensive summary of findings from clinical trials investigating the use of BTKi in MCL treatment and offers valuable insights for clinical practice.

Key words: BTK inhibitor, relapsed, refractory, mantle cell lymphoma, targeted therapy

CLC Number:

R551.2

Sishi XU,Peipei. YE. Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma[J]. The Journal of Practical Medicine, 2024, 40(17): 2363-2368.

References 42

1	ARMITAGE J O， LONGO D L. Mantle-Cell Lymphoma［J］. N Engl J Med， 2022，386（26）：2495-2506. doi:10.1056/nejmra2202672 doi: 10.1056/nejmra2202672
2	MCCULLOCH R， VISCO C， EYRE T A，et al. Efficacy of R-BAC in relapsed， refractory mantle cell lymphoma post BTK inhibitor therapy［J］. Br J Haematol，2020，189（4）：684-688. doi:10.1111/bjh.16416 doi: 10.1111/bjh.16416
3	LU T， ZHANG J， MCCRACKEN J M，et al. Recent advances in genomics and therapeutics in mantle cell lymphoma［J］. Cancer Treat Rev， 2024，（122）：102651. doi:10.1016/j.ctrv.2023.102651 doi: 10.1016/j.ctrv.2023.102651
4	董佳艺，邵丽娟，郑柱，等. 嵌合抗原受体T细胞联合分子靶向药治疗实体瘤研究进展［J］. 实用医学杂志，2023，39（7）：798-803.
5	ESTUPIÑÁN H Y， WANG Q， BERGLÖF A，et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib，ibrutinib and zanubrutinib［J］. Leukemia，2021，35（5）：1317-1329. doi:10.1038/s41375-021-01123-6 doi: 10.1038/s41375-021-01123-6
6	KEAM S J. Pirtobrutinib： First Approval［J］. Drugs，2023，83（6）：547-553. doi:10.1007/s40265-023-01860-1 doi: 10.1007/s40265-023-01860-1
7	RULE S， DREYLING M，GOY A，et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib：a pooled analysis from three open‐label studies［J］. Br J Haematol，2017，179（3）：430-438. doi:10.1111/bjh.14870 doi: 10.1111/bjh.14870
8	DREYLING M， JURCZAK W， JERKEMAN M，et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma：an international，randomised，open-label，phase 3 study［J］. Lancet，2016，387（10020）：770-778. doi:10.1016/s0140-6736(15)00667-4 doi: 10.1016/s0140-6736(15)00667-4
9	ESTUPIÑÁN H Y， BERGLÖF A， ZAIN R，et al. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects［J］. Front Cell Dev Biol，2021，9：630942. doi:10.3389/fcell.2021.630942 doi: 10.3389/fcell.2021.630942
10	JERKEMAN M， ESKELUND C W， HUTCHINGS M，et al. Ibrutinib， lenalidomide，and rituximab in relapsed or refractory mantle cell lymphoma （PHILEMON）： A multicentre，open-label，single-arm，phase 2 trial［J］. Lancet Haematol，2018，5（3）：e109-e116. doi:10.1016/s2352-3026(18)30018-8 doi: 10.1016/s2352-3026(18)30018-8
11	TAM C S， ANDERSON M A， POTT C，et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma［J］. N Engl J Med，2018， 378（13）：1211-1223. doi:10.1056/nejmoa1715519 doi: 10.1056/nejmoa1715519
12	LE GOUILL S， MORSCHHAUSER F， CHIRON D，et al. Ibrutinib， obinutuzumab，and venetoclax in relapsed and untreated patients with mantle cell lymphoma： A phase 1/2 trial［J］. Blood，2021，137（7）：877-887. doi:10.1182/blood.2020008727 doi: 10.1182/blood.2020008727
13	DAVIDS M S， KIM H T， NICOTRA A，et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma： a multicentre phase 1-1b study［J］. Lancet Haematol，2019，6（1）：e38-e47.
14	MARTIN P， BARTLETT N L， BLUM K A，et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma［J］. Blood， 2019，133（11）：1201-1204. doi:10.1182/blood.2019002741 doi: 10.1182/blood.2019002741
15	WANG M， RAMCHANDREN R， CHEN R，et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma：the safety run-in of the phase 3 SYMPATICO study［J］. J Hematol Oncol， 2021， 14（1）：179. doi:10.1186/s13045-021-01188-x doi: 10.1186/s13045-021-01188-x
16	TIVEY A， SHOTTON R， EYRE T A，et al. Ibrutinib as first line therapy for mantle cell lymphoma：A multicentre，real-world UK study［J］. Blood Adv， 2024，8（5）：1209-1219.
17	WANG M L， JURCZAK W， JERKEMAN M，et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma［J］. N Engl J Med， 2022，386（26）：2482-2494. doi:10.1056/nejmoa2201817 doi: 10.1056/nejmoa2201817
18	Update on IMBRUVICA^® （ibrutinib） U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications［EB ］（2023-04-06）［2024-02-03］ . .
19	DREYLING M， DOORDUIJN J K， GINE E，et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma （TRIANGLE）： a three-arm，randomised， open-label，phase 3 superiority trial of the European Mantle Cell Lymphoma Network［J］. Lancet，2024，403（10441）：2293-2306.
20	IZUTSU K， ANDO K， ENNISHI D，et al. Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies：A Japanese phase I study［J］. Cancer Sci， 2021，112（6）：2405-2415. doi:10.1111/cas.14886 doi: 10.1111/cas.14886
21	LE GOUILL S， DŁUGOSZ-DANECKA M， RULE S，et al. Final results and overall survival data from a phase Ⅱ study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma，including those with poor prognostic factors［J］. Haematologica， 2024，109（1）：343-350.
22	KIM A I， ARMAND P， REDD R A，et al. Phase I Safety and Preliminary Efficacy of Acalabrutinib，Venetoclax，and Obinutuzumab （AVO） in Patients with Relapsed/Refractory Mantle Cell Lymphoma［J］. Blood， 2023，142（）：3031. doi:10.1182/blood-2023-173103 doi: 10.1182/blood-2023-173103
23	BAIRD J H， DEL REAL M M， SONG J Y，et al. CD19-Directed CAR T-Cells （CD19-CAR） Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory （r/r） Mantle Cell Lymphoma （MCL）［J］. Blood，2023，142（）：4840. doi:10.1182/blood-2023-182456 doi: 10.1182/blood-2023-182456
24	POH C， CHOW V A， LYNCH R C，et al. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma：A Phase Ⅰ/ⅡStudy of Safety， Efficacy and Immune Correlative Analysis［J］.Blood，2023，142 （）：2129.
25	VILLA D， LAROUCHE J F， CHEUNG M C，et al. Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma： The Rectangle Trial［J］. Blood，2023，142 （）：3042. doi:10.1182/blood-2023-179375 doi: 10.1182/blood-2023-179375
26	HAWKES E A， LEE S T， CHURILOV L，et al. A Window Study of Acalabrutinib & Rituximab， Followed By Chemotherapy & Autograft （ASCT） in Fit Patients with Treatment Naive Mantle Cell Lymphoma （MCL）：First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 “Wamm” Trial［J］. Blood，2023，142（）：735. doi:10.1182/blood-2023-178403 doi: 10.1182/blood-2023-178403
27	WANG M， ROBAK T， MADDOCKS K J，et al. Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve （TN） Mantle Cell Lymphoma （MCL）［J］.Blood，2021，138（）： 2416. doi:10.1182/blood-2021-146615 doi: 10.1182/blood-2021-146615
28	HAWKES E A， FLETCHER R， WOOD A，et al. Traverse： A Phase 2， Open-Label， Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma［J］. Blood，2023， 142（）：3054.
29	ZHOU K， ZOU D， ZHOU J，et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma： a pooled analysis of two clinical trials［J］. J Hematol Oncol，2021，14（1）：167. doi:10.1186/s13045-021-01174-3 doi: 10.1186/s13045-021-01174-3
30	KUMAR A， SOUMERAI J， ABRAMSON J S，et al. A Multicenter Phase 2 Trial of Zanubrutinib，Obinutuzumab，and Venetoclax （BOVen） in Patients with Treatment-Naive， TP53-Mutant Mantle Cell Lymphoma［J］. Blood，2023，142（）：738. doi:10.1182/blood-2023-180069 doi: 10.1182/blood-2023-180069
31	HILL H A， QI X， JAIN P，et al. Genetic mutations and features of mantle cell lymphoma： a systematic review and meta-analysis［J］. Blood Adv， 2020，4（13）：2927-2938. doi:10.1182/bloodadvances.2019001350 doi: 10.1182/bloodadvances.2019001350
32	DENG L J， ZHOU K S， LIU L H，et al. Orelabrutinib for the treatment of relapsed or refractory MCL：a phase 1/2，open-label， multicenter，single-arm study［J］. Blood Adv， 2023，7（16）：4349-4357. doi:10.1182/bloodadvances.2022009168 doi: 10.1182/bloodadvances.2022009168
33	DHILLON S. Orelabrutinib： First Approval［J］. Drugs， 2021，81（4）： 503-507.
34	ZHANG H， SU L， LIU L，et al. A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab（OLR） in Patients with Untreated Mantle Cell Lymphoma（MCL） in China（POLARIS Study）： Preliminary Analysis on Efficacy，Safety，Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses［J］. Blood， 2023，142（）：736. doi:10.1182/blood-2023-178509 doi: 10.1182/blood-2023-178509
35	GOMEZ E B， EBATA K， RANDERIA H S，et al. Preclinical characterization of pirtobrutinib， a highly selective，noncovalent（reversible） BTK inhibitor［J］. Blood， 2023，142（1）：62-72.
36	MATO A R， SHAH N N， JURCZAK W，et al. Pirtobrutinib in relapsed or refractory B-cell malignancies（BRUIN）：a phase 1/2 study［J］. Lancet， 2021，397（10277）：892-901. doi:10.1016/s0140-6736(21)00224-5 doi: 10.1016/s0140-6736(21)00224-5
37	COHEN J B， SHAH N N， JURCZAK W，et al. Pirtobrutinib in Relapsed/Refractory（R/R） Mantle Cell Lymphoma（MCL） Patients with Prior cBTKi：Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study［J］. Blood，2023，142（）：981. doi:10.1182/blood-2023-181627 doi: 10.1182/blood-2023-181627
38	EYRE T A， SHAH N N， DREYLING M，et al. BRUIN MCL-321：phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma［J］. Future Oncol， 2022， 18（36）：3961-3969.
39	RULE S A， CARTRON G， FEGAN C，et al. Long-term follow-up of patients with mantle cell lymphoma（MCL） treated with the selective Bruton′s tyrosine kinase inhibitor tirabrutinib（GS/ONO-4059）［J］. Leukemia， 2020，34（5）：1458-1461. doi:10.1038/s41375-019-0658-7 doi: 10.1038/s41375-019-0658-7
40	ELGAMAL O A， MEHMOOD A， JEON J Y，et al. Preclinical efficacy for a novel tyrosine kinase inhibitor， ArQule 531 against acute myeloid leukemia［J］. J Hematol Oncol， 2020，13（1）：8. doi:10.1186/s13045-019-0821-7 doi: 10.1186/s13045-019-0821-7
41	WOYACH J A， STEPHENS D M， FLINN I W，et al. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma［J］. Cancer Discov，2024，14（1）：66-75. doi:10.1158/2159-8290.cd-23-0670 doi: 10.1158/2159-8290.cd-23-0670
42	MATO A R， WIERDA W G， AI W Z，et al. NX-2127-001， a First-in-Human Trial of NX-2127， a Bruton′s Tyrosine Kinase-Targeted Protein Degrader， in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies［J］. Blood，2022，140（）： 2329-2332.

[1]	Fazhu FEI,Jiajun LU,Shuai ZHANG,Hao LI,Bin REN. Clinical application progress of immunization and targeted therapy for Hepatocellular Carcinoma in special populations [J]. The Journal of Practical Medicine, 2024, 40(6): 738-742.
[2]	Qianqian CHEN,Qiuyu LIN,Xiangyun ZHANG,Dufei. ZHANG. Relationship between macrolide⁃resistant mycoplasma pneumoniae infection and refractory Mycoplasma pneumoniae pneumonia in children [J]. The Journal of Practical Medicine, 2024, 40(22): 3190-3195.
[3]	Yuting LI,Qilu YAN,Qibin. SONG. Molecular basis of variability in EGFR⁃targeted therapy response in non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(15): 2166-2171.
[4]	Qinglin HU,Ziqi WAN,Chen YANG,Miao CHEN,Bing HAN. Efficacy and safety of Roxadustat in the treatment of refractory NSAA and low-risk MDS-related anemia [J]. The Journal of Practical Medicine, 2024, 40(12): 1719-1724.
[5]	Jingwen AN,Junyun FENG,Lei RAO,Dewu LIU. Research progress on relationship between cellular senescence and scar fibrosis [J]. The Journal of Practical Medicine, 2024, 40(12): 1749-1754.
[6]	WANG Min, XING Lingling, ZHANG Chunxia, LU Suyu, WU Xiaolei, XU Longyun, JIANG Zujuan, LI Shao⁃ mei, PEI Huaying.. Influence of refractory peritoneal dialysis ⁃ associated peritonitis and the prediction of extubation risk [J]. The Journal of Practical Medicine, 2023, 39(9): 1143-1147.
[7]	BAI Ziye, WANG Huaigu, ZHANG Li, ZHU Kun, CUI Lei, HAN Na, WANG Shuo.. Efficacy of local oxygen therapy combined with rb ⁃ bFGF and negative pressure drainage technology in chronic refractory wounds [J]. The Journal of Practical Medicine, 2022, 38(20): 2561-2567.
[8]	YU Tao.. Individualized brain stimulation strategy：A new perspective of neuromodulation for refractory epilepsy [J]. The Journal of Practical Medicine, 2022, 38(17): 2117-2122.
[9]	LIU Yi, PEI Renzhi.. Advances of BCL ⁃ 2 inhibitor Venetoclaxfor higher ⁃ risk groups of myelodysplastic syndromes [J]. The Journal of Practical Medicine, 2022, 38(16): 2106-2109.
[10]	NIU Chunyan, SHI Yongqiang, CHEN Yue.. Targeted therapeutic drugs for nonalcoholic fatty liver disease：A review of literature [J]. The Journal of Practical Medicine, 2022, 38(11): 1439-1442.
[11]	NIU Meina, WANG Haicui, ZHU Shuangshuang, WANG Xiaowei, LI Mei⁃ rong.. Efficacy of double⁃dose esomeprazole，mosapride combined with tandospirone in the treatment of refracto⁃ ry gastroesophageal reflux disease [J]. The Journal of Practical Medicine, 2022, 38(1): 90-95.
[12]	LIN Beibei, HUANG Xiaoqiao, YAO Meicun, FENG Weixun, FENG Xiangxing, ZHU Shaoqin, ZHU Weixing, GAN Guoxing, YANG Xiaocui.. Early Banxia Xiexin decoction and late Xiangsha Liujunzi decoction combined with chinese medicine Diyu and triple therapy for treatment of refractory Helicobacter pylori infection in stages [J]. The Journal of Practical Medicine, 2021, 37(6): 811-815.
[13]	LI Depei, CHEN Zhongping.. Current statue and advances of treatment for gliomas [J]. The Journal of Practical Medicine, 2021, 37(18): 2312-2316.
[14]	SU Ruifeng, LI Xiaohong, LI Xinxiu, TAN Xiaobo.. Effect of inner limiting membrane peeling on refractory diabetic macular edema and visual function [J]. The Journal of Practical Medicine, 2021, 37(14): 1811-1814.
[15]	GUAN Zheng, HUO Jie, YUAN Jing, WU Xinping. Effect of LDH and IL ⁃ 18 on prediction of refractory mycoplasma pneumoniae pneumonia in children [J]. The Journal of Practical Medicine, 2020, 36(20): 2848-2851.

Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Recommended Articles

Metrics

Comments